title: Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data.
abstract: We modified criteria for judging successful obesity treatment proposed by Atkinson to provide objective criteria for successful benefit from weight reduction programs with respect to data from a clinical trial. The criteria include assessments of changes in both weight-related factors (e.g. excess weight, excess body fat) and obesity-related risk factors (e.g. hypertension, hyperglycemia, hyperlipemia). To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss. The results suggest these criteria can be useful for evaluating a treatment program or for comparing treatments from clinical trials.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
authors.forename: M E
authors.initials: ME
authors.lastname: Sayler
authors.forename: D J
authors.initials: DJ
authors.lastname: Goldstein
authors.forename: P J
authors.initials: PJ
authors.lastname: Roback
authors.forename: R L
authors.initials: RL
authors.lastname: Atkinson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004038:Diet, Reducing / Q000592:standards*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D015397:Program Evaluation; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology*
chemical_list: D005473:Fluoxetine